Patents by Inventor Fumiko Nomura
Fumiko Nomura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230250180Abstract: It is an object of the present invention to provide a therapeutic drug for carcinomatous peritonitis. According to the present invention, a therapeutic drug for carcinomatous peritonitis which comprises an antibody which recognizes a transferrin receptor, is provided.Type: ApplicationFiled: November 27, 2020Publication date: August 10, 2023Applicants: PERSEUS PROTEOMICS INC., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITYInventors: Fumiko NOMURA, Tadashi MATSUURA, Lilin ZHANG, Yoichi AIKAWA, Takayuki ASAO, Takehiko YOKOBORI
-
Publication number: 20230220098Abstract: It is an object of the present invention to provide a therapeutic drug for polycythemia. According to the present invention, provided is a therapeutic drug for polycythemia, comprising an antibody which recognizes the amino acids at positions 629 to 633 of a human transferrin receptor.Type: ApplicationFiled: September 4, 2020Publication date: July 13, 2023Applicants: PERSEUS PROTEOMICS INC., JUNTENDO EDUCATIONAL FOUNDATIONInventors: Lilin ZHANG, Fumiko NOMURA, Norio KOMATSU, Marito ARAKI
-
Publication number: 20220332838Abstract: It is an object of the present invention to provide an agent for inhibiting iron uptake into cells wherein the agent targets TfR, and an agent for inhibiting the binding between human Tf and human TfR. The present invention provides an agent for inhibiting iron uptake into cells which comprises an antibody which recognizes the amino acids at positions 629 to 633 of a human transferrin receptor.Type: ApplicationFiled: November 19, 2019Publication date: October 20, 2022Applicant: PERSEUS PROTEOMICS INC.Inventors: Lilin ZHANG, Fumiko NOMURA, Keiko KATSUMI, Romi KOTAKA, Yuta OHIRA
-
Patent number: 9764041Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.Type: GrantFiled: April 4, 2012Date of Patent: September 19, 2017Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
-
Patent number: 9644028Abstract: The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.Type: GrantFiled: February 14, 2014Date of Patent: May 9, 2017Assignee: PERSEUS PROTEOMICS INC.Inventors: Keisuke Ishii, Katsuyuki Mitomo, Katsushi Kouda, Fumiko Nomura, Yoko Kayukawa, Tadashi Matsuura
-
Patent number: 9598496Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: GrantFiled: May 7, 2012Date of Patent: March 21, 2017Assignees: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Patent number: 9593165Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: GrantFiled: November 8, 2013Date of Patent: March 14, 2017Assignees: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20160152703Abstract: It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No.Type: ApplicationFiled: February 14, 2014Publication date: June 2, 2016Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
-
Publication number: 20160058883Abstract: It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.Type: ApplicationFiled: April 4, 2012Publication date: March 3, 2016Applicant: PERSEUS PROTEOMICS INC.Inventors: Keisuke ISHII, Katsuyuki MITOMO, Katsushi KOUDA, Fumiko NOMURA, Yoko KAYUKAWA, Tadashi MATSUURA
-
Publication number: 20150291697Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: ApplicationFiled: November 8, 2013Publication date: October 15, 2015Applicants: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20140328754Abstract: A radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: ApplicationFiled: June 18, 2014Publication date: November 6, 2014Applicants: Fujifilm RI Pharma Co., LTD, Perseus Proteomics Inc.Inventors: Akihiro HINO, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Patent number: 8815211Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: GrantFiled: February 9, 2011Date of Patent: August 26, 2014Assignees: Fujifilm RI Pharma Co., Ltd., Perseus Proteomics Inc.Inventors: Akihiro Hino, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo
-
Publication number: 20140114054Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: ApplicationFiled: May 7, 2012Publication date: April 24, 2014Applicants: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20130071324Abstract: An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.Type: ApplicationFiled: February 9, 2011Publication date: March 21, 2013Applicants: PERSEUS PROTEOMICS INC., FUJIFILM RI PHARMA CO., LTD.Inventors: Akihiro Hino, Akio Nagano, Masahiko Watanabe, Tadasi Matsuura, Hirokazu Satoh, Fumiko Nomura, Katsuyuki Mitomo